Adjuvant system AS01: helping to overcome the challenges of modern vaccines

References

• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287–293.
   PubMed Web of Science ®Google Scholar
• Wilson-Welder JH, Torres MP, Kipper MJ, et al. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci. 2009;98:1278–1316.
   PubMed Web of Science ®Google Scholar
• Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19:1597–1608.
   PubMed Web of Science ®Google Scholar
• Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013;4:114.
   PubMed Web of Science ®Google Scholar
• Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10;471–486.
   PubMed Web of Science ®Google Scholar
• Baldridge JR, McGowan P, Evans JT, et al. Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther. 2004;4:1129–1138.
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol Baltim Md. 1950 2009;183:6186–6197.
   Google Scholar
• Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci CMLS. 2008;65:3231–3240.
   PubMed Web of Science ®Google Scholar
• Newman MJ, Wu JY, Gardner BH, et al. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine. 1997;15:1001–1007.
   PubMed Web of Science ®Google Scholar
• Kashala O, Amador R, Valero MV, et al. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine. 2002;20:2263–2277.
   PubMed Web of Science ®Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007;6:723–739.
   PubMed Web of Science ®Google Scholar
• Beck Z, Matyas GR, Alving CR. Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. Biochim Biophys Acta. 2015;1848:775–780.
   PubMed Web of Science ®Google Scholar
• Marty-Roix R, Vladimer GI, Pouliot K, et al. Identification of QS-21 as an Inflammasome-activating molecular component of saponin adjuvants. J Biol Chem. 2016;291:1123–1136.
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Malaria Report. 2014. [cited 2015 Jul 31]. Available from: http://www.who.int/malaria/publications/world_malaria_report_2014/en/
   Google Scholar
• Ferreira MU, Da Silva Nunes M, Wunderlich G. Antigenic diversity and immune evasion by malaria parasites. Clin Diagn Lab Immunol. 2004;11:987–995.
   PubMedGoogle Scholar
• Morrot A, Rodrigues MM. Tissue signatures influence the activation of intrahepatic CD8(+) T cells against malaria sporozoites. Front Microbiol. 2014;5:440.
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833.
   PubMed Web of Science ®Google Scholar
• Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother. 2004;5:551–559.
   PubMed Web of Science ®Google Scholar
• Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24:494–500.
   PubMed Web of Science ®Google Scholar
• Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197:S58–S60.
   PubMed Web of Science ®Google Scholar
• Burke BL, Steele RW, Beard OW, et al. Immune responses to varicella-zoster in the aged. Arch Intern Med. 1982;142:291–293.
   PubMed Web of Science ®Google Scholar
• Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med. 2007;9:1–17.
   PubMedGoogle Scholar
• Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012;206:1280–1290.
   PubMed Web of Science ®Google Scholar
• Arvin AM, Kinney-Thomas E, Shriver K, et al. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol Baltim Md. 1950 1986;137:1346–1351.
   Google Scholar
• Berkowitz EM, Moyle G, Stellbrink H-J, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211:1279–1287.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921–2929.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency - Human medicines - Zostavax. 2016. [cited 2016 Mar 22]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000674/human_med_001185.jsp&mid=WC0b01ac058001d125
   Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33;492–503.
   PubMed Web of Science ®Google Scholar
• Duthie MS, Windish HP, Fox CB, et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 2011;239:178–196.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Ott GS, De Gregorio E, et al. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012;30:4341–4348.
   PubMed Web of Science ®Google Scholar
• Pearse MJ, Drane D. ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses. Vaccine. 2004;22:2391–2395.
   PubMed Web of Science ®Google Scholar
• Di Pasquale A, Preiss S, Tavares Da Silva F, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines. 2015;3;320–343.
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant system AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011;29:2461–2473.
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193:1920–1930.
   PubMed Web of Science ®Google Scholar
• Wilson NS, Yang B, Morelli AB, et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol. 2012;90:540–552.
   PubMed Web of Science ®Google Scholar
• Mettens P, Dubois PM, Demoitié M-A, et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine. 2008;26:1072–1082.
   PubMed Web of Science ®Google Scholar
• Dendouga N, Fochesato M, Lockman L, et al. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012;30;3126–3135.
   PubMed Web of Science ®Google Scholar
• Fochesato M, Dendouga N, Boxus M. Comparative preclinical evaluation of AS01 versus other adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine. Hum Vaccines Immunother. 2016 Mar 2;1–4. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Groom JR, Richmond J, Murooka TT, et al. CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. Immunity. 2012;37:1091–1103.
   PubMed Web of Science ®Google Scholar
• Vandepapelière P, Horsmans Y, Moris P, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine. 2008;26:1375–1386.
   PubMed Web of Science ®Google Scholar
• Olotu A, Moris P, Mwacharo J, et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PloS One. 2011;6:e25786.
   PubMed Web of Science ®Google Scholar
• Ansong D, Asante KP, Vekemans J, et al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PloS One. 2011;6:e18891.
   PubMed Web of Science ®Google Scholar
• Owusu-Agyei S, Ansong D, Asante K, et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PloS One. 2009;4(10):e7302.
   PubMed Web of Science ®Google Scholar
• Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200:337–346.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Leroux-Roels I, Clement F, et al. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults. Hum Vaccines Immunother. 2014;10:2211–2219.
   PubMed Web of Science ®Google Scholar
• RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685.
   PubMed Web of Science ®Google Scholar
• RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45.
   PubMed Web of Science ®Google Scholar
• Penny MA, Verity R, Bever CA, et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016;387:367–375.
   PubMed Web of Science ®Google Scholar
• RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863–1875.
   PubMed Web of Science ®Google Scholar
• Lusingu J, Olotu A, Leach A, et al. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian children. PloS One. 2010;5:e14090.
   PubMed Web of Science ®Google Scholar
• Asante KP, Abdulla S, Agnandji S, et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011;11:741–749.
   PubMed Web of Science ®Google Scholar
• RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284–2295.
   PubMed Web of Science ®Google Scholar
• Vekemans J, Guerra Y, Lievens M, et al. Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials. Hum Vaccin. 2011;7:1309–1316.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Mosquirix H-W-2300. European public assessment report [cited 2016 Mar 22]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/document_listing/document_listing_000395.jsp&mid=
   Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–2096.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency - News and Events - First malaria vaccine receives positive scientific opinion from EMA. [cited 2016 Mar 22]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/07/news_detail_002376.jsp&mid=WC0b01ac058004d5c1
   Google Scholar
• Penn-Nicholson A, Geldenhuys H, Burny W, et al. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine. 2015;33:4025–4034.
   PubMed Web of Science ®Google Scholar
• Stassijns J, Bollaerts K, Baay M, et al. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine. 2016;34;714–722.
   PubMed Web of Science ®Google Scholar
• Garçon N, Leroux-Roels G, Cheng W. Vaccine adjuvants. In: Garçon N, Stern PL, Cunningham AL, et al., editors. Understanding modern vaccines: perspectives in vaccinology. Elsevier; 2011. p. 89–113.
   Google Scholar